ArticleCureus2025
The Promise of Exome Sequencing for the Differential Diagnosis of Late-Onset End-Stage Renal Disease in Turkish Cypriots.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
End-stage renal disease (ESRD) is a pathophysiological condition that requires radical solutions for treatment. Although ESRD is a worldwide health problem, the incidence of the disease is relatively high in the Mediterranean island of Cyprus. Moreover, the etiology of the disease largely remains poorly understood. Overlapping diseases such as diabetes mellitus may pose a challenge during the differential diagnosis of ESRD. Hence, molecular diagnosis could be powerful in terms of ESRD diagnosis. Nevertheless, the genetic isolation of Cyprus and the complexity of the disease necessitate more comprehensive, population-based approaches. In the current study, exome sequencing (ES) data obtained from 24 Turkish Cypriot patients with ESRD were re-analyzed. Variants were filtered according to the allele frequencies in population databases and the renal anomalies-related gene list. Variants were then prioritized according to the guidelines of the American College of Medical Genetics. The re-analysis underscored that different genes and their variants could explain the molecular mechanisms of the disease. However, numerous variants were found to be prevalent in all patients, limiting the ability to reach a population-based conclusion about the aetiology of ESRD in Cyprus. Although ES could be useful for the molecular diagnosis of ESRD, further population-based cohort studies and a whole genome database with data from healthy participants are still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.